Myriad Genetics (MYGN)
(Delayed Data from NSDQ)
$18.18 USD
+0.20 (1.11%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $18.17 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.18 USD
+0.20 (1.11%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $18.17 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum C VGM
Zacks News
Myriad Genetics (MYGN), Illumina Partner to Enhance Oncology Arm
by Zacks Equity Research
Myriad Genetics (MYGN) partners with Illumina to expand the access as well as extend the reach of myChoice CDx through its services offering in the international market.
Why Is Myriad (MYGN) Up 8.3% Since Last Earnings Report?
by Zacks Equity Research
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Myriad Genetics' (MYGN) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Myriad Genetics' (MYGN) sales in majority of the operating segments plummeted in the quarter owing to the pandemic-led business challenges.
Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Myriad (MYGN) delivered earnings and revenue surprises of 54.55% and 7.86%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Myriad Genetics (MYGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Buy 4 Beaten-Down MedTech Value Stocks Amid September Selloffs
by Debanjana Dey
Here are some dirt-cheap MedTech value stocks which have been battered by the pandemic-led market meltdown and can be considered for long-term gains.
Myriad (MYGN) Down 0.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights: Medtronic, Abbott Laboratories, Myriad Genetics, Zimmer Biomet and General Electric
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Medtronic, Abbott Laboratories, Myriad Genetics, Zimmer Biomet and General Electric
3 Coronavirus-Led Threats to MedTech That May Linger
by Urmimala Biswas
Let us delve deeper to get an insight into the not-so-talked-about but intense threats to MedTech.
ASCO Recommends Myriad Genetics' Test to Treat Ovarian Cancer
by Zacks Equity Research
Myriad Genetics' (MYGN) myChoice CDx test gets included in ASCO's latest recommendations for advanced ovarian cancer patients.
Myriad Genetics' (MYGN) Q4 Loss Narrower Than Estimated
by Zacks Equity Research
Myriad Genetics (MYGN) sales in each of the operating segments plummet in the quarter owing to the full-quarter adverse impact of the pandemic.
Myriad Genetics (MYGN) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Myriad (MYGN) delivered earnings and revenue surprises of 13.89% and -2.34%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Myriad Genetics (MYGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Affordable MedTech Growth Stocks to Buy Amid Market Unrest
by Debanjana Dey
Here are some MedTech stocks which might be a solid investment option amid the coronavirus-battered market conditions.
Myriad Genetics, OptraHEALTH Partner to Offer Cancer Knowledge
by Zacks Equity Research
Myriad Genetics (MYGN) collaborates with OptraHEALTH to provide an AI-powered cognitive ChatBOT to serve as a genetic health knowledge platform to prospective hereditary cancer patients.
Myriad Genetics Rides on EndoPredict Amid Coronavirus Crisis
by Zacks Equity Research
Myriad Genetics (MYGN) expects to register an uptick in hereditary cancer volumes on account of its contract with UnitedHealthcare.
Myriad Genetics Unveils New Home DNA Sample Collection Kit
by Zacks Equity Research
Myriad Genetics' (MYGN) home DNA sample collection test kit for its GeneSight Psychotropic test enables physicians to remotely provide treatment options to patients with mental health issues.
Myriad Genetics' myPath Melanoma Proved Superior Per New Study
by Zacks Equity Research
Myriad Genetics' (MYGN) myPath Melanoma's accuracy to classify skin lesions, termed as indeterminate by standard pathological review, validated by the latest study.
Zacks.com featured highlights include: Myriad Genetics, Casella Waste, CNH and Schlumberger
by Zacks Equity Research
Zacks.com featured highlights include: Myriad Genetics, Casella Waste, CNH and Schlumberger
4 Toxic Stocks to Disown or Play Short to Book Profits
by Zacks Equity Research
If you are a smart investor and can precisely spot toxic stocks, you may gain by resorting to an investing strategy called short selling.
Myriad Genetics' Prolaris Receives Favorable Coverage Policies
by Zacks Equity Research
Myriad Genetics (MYGN) paves the way for bringing more prostate cancer patients under the purview of Prolaris testing through their health plan.
Myriad Genetics' Test Better Predicts Drug Levels Per Study
by Zacks Equity Research
Myriad Genetics' (MYGN) GeneSight Psychotropic test is shown to be superior at predicting blood concentrations unlike single-gene testing as demonstrated by a latest study.
Keep These 4 Toxic Stocks Off Your Portfolio to Avoid Losses
by Zacks Equity Research
Identifying toxic stocks and discarding them at the right time is the key to guard your portfolio from big losses.
Why Is Myriad (MYGN) Up 8.9% Since Last Earnings Report?
by Zacks Equity Research
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks.com featured highlights include: Myriad Genetics, Cinemark, Vericel and IDEXX Laboratories
by Zacks Equity Research
Zacks.com featured highlights include: Myriad Genetics, Cinemark, Vericel and IDEXX Laboratories